About 1E Therapeutics

Develops programmable oligonucleotide therapeutics that autonomously silence disease-causing RNAs in human and pathogen cells. This platform targets genetically driven diseases, chronic conditions, and multidrug-resistant infections, offering safer and more precise treatments for conditions like cancer, ALS, and MRSA.

```xml <problem> Many diseases are driven by the expression of specific RNAs within human and pathogen cells. Current treatment options for these diseases may lack the precision to target the underlying genetic causes or may have significant side effects. </problem> <solution> 1E Therapeutics is developing a new class of programmable oligonucleotide therapeutics designed to autonomously silence disease-causing RNAs in human and pathogen cells. Their patented platform creates targeted therapies that address chronic and life-threatening indications, as well as emerging and evolving pathogens. This approach offers the potential for safer and more precise treatments for a wide array of indications, including genetically driven diseases, infectious diseases, and chronic conditions. By directly silencing the RNAs responsible for disease, 1E Therapeutics aims to provide more effective and targeted therapeutic interventions. </solution> <features> - Programmable oligonucleotide therapeutics for targeted RNA silencing - Patented platform for creating safer and more targeted therapies - Ability to address a wide array of indications, including genetically driven diseases, infectious diseases, and chronic conditions - Designed to autonomously and precisely silence disease-causing RNAs in human or pathogen cells </features> <target_audience> The primary target audience includes patients suffering from genetically driven diseases, chronic conditions, and multidrug-resistant infections, as well as healthcare providers seeking more precise and effective treatment options. </target_audience> ```

What does 1E Therapeutics do?

Where is 1E Therapeutics located?

1E Therapeutics is based in רחובות, ישראל.

When was 1E Therapeutics founded?

1E Therapeutics was founded in 2020.

How much funding has 1E Therapeutics raised?

1E Therapeutics has raised 120000000.

Location

רחובות, ישראל

Founded

2020

Funding

120000000

Employees

49 employees

Major Investors

Marius Nacht

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

1E Therapeutics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

1etx.com 2K+

Crunchbase

Founded 2020 – רחובות, ישראל

Funding

Estimated Funding

$100M+

Major Investors

Marius Nacht

Team (40+)

No team information available.

Company Description

Problem

Many diseases are driven by the expression of specific RNAs within human and pathogen cells. Current treatment options for these diseases may lack the precision to target the underlying genetic causes or may have significant side effects.

Solution

1E Therapeutics is developing a new class of programmable oligonucleotide therapeutics designed to autonomously silence disease-causing RNAs in human and pathogen cells. Their patented platform creates targeted therapies that address chronic and life-threatening indications, as well as emerging and evolving pathogens. This approach offers the potential for safer and more precise treatments for a wide array of indications, including genetically driven diseases, infectious diseases, and chronic conditions. By directly silencing the RNAs responsible for disease, 1E Therapeutics aims to provide more effective and targeted therapeutic interventions.

Features

Programmable oligonucleotide therapeutics for targeted RNA silencing

Patented platform for creating safer and more targeted therapies

Ability to address a wide array of indications, including genetically driven diseases, infectious diseases, and chronic conditions

Designed to autonomously and precisely silence disease-causing RNAs in human or pathogen cells

Target Audience

The primary target audience includes patients suffering from genetically driven diseases, chronic conditions, and multidrug-resistant infections, as well as healthcare providers seeking more precise and effective treatment options.